New Study to Evaluate Tibulizumab in Systemic Sclerosis A randomized, double-blind, placebo-controlled study will assess the efficacy, safety, and tolerability of tibulizumab in adults with diffuse cutaneous SSc.

#SSWC2026: A randomized, double-blind, placebo-controlled study (TibuSURE, #NCT06843239) is looking to assess the efficacy, safety, and tolerability of #Tibulizumab in adults with diffuse cutaneous #SystemicSclerosis (SSc).

Learn more: https://bit.ly/4loDQFR

#RareDisease #SSc #TibuSURE

Huge thanks 👏 to the congress organisers and #WSF for the invite to present my work @ucd-chas.bsky.social on fibroblast-immune cell interactions at #SSWC2026 🫁 special thanks to #WSF who fund the work 😀 Lovely to catch up with colleagues and make new connections #SSc-ILD @ucdresearch.bsky.social